+关注
chantow
暂无个人介绍
IP属地：未知
1
关注
0
粉丝
0
主题
0
勋章
主贴
热门
chantow
2021-04-27
Good read
5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote>
chantow
2021-04-27
TESLA FTW
Tesla posts record net income of $438 million, revenue surges by 74%<blockquote>特斯拉净利润创纪录4.38亿美元营收暴增74%</blockquote>
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3580731839183444","uuid":"3580731839183444","gmtCreate":1617671423925,"gmtModify":1617671423925,"name":"chantow","pinyin":"chantow","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.31","exceedPercentage":"93.81%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.11","exceedPercentage":"80.73%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":377581011,"gmtCreate":1619535680733,"gmtModify":1634211958870,"author":{"id":"3580731839183444","authorId":"3580731839183444","name":"chantow","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580731839183444","authorIdStr":"3580731839183444"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/377581011","repostId":"1112397012","repostType":4,"repost":{"id":"1112397012","kind":"news","pubTimestamp":1619521537,"share":"https://www.laohu8.com/m/news/1112397012?lang=zh_CN&edition=full","pubTime":"2021-04-27 19:05","market":"us","language":"en","title":"5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1112397012","media":"Motley Fool","summary":"For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% ","content":"<p>For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmark<b>S&P 500</b>has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.</p><p><blockquote>一年多来，投资者一直被华尔街史诗般的反弹宠坏了。在2020年第一季度短短33个日历日内损失了34%的价值后，该基准<b>标普500</b>自2020年3月23日触及熊市底部以来，截至上周末，股价已飙升87%。</blockquote></p><p>Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.</p><p><blockquote>尽管大盘股（市值至少100亿美元的公司）一直是这次反弹的明星，但华尔街认为小盘股（市值3亿至20亿美元）已经准备好大放异彩。小盘股通常风险更大，因为它们的运营模式未经时间考验或验证。但与更成熟的公司相比，它们通常可以提供更好的增长前景。</blockquote></p><p>Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.</p><p><blockquote>根据华尔街分析师一致的一年目标价，以下五只小盘股均提供60%至高达140%的上涨空间。</blockquote></p><p><img src=\"https://static.tigerbbs.com/e84aa34310d37f1ab30212f9dcf1bf0d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Vaxart: Implied upside of 140%</p><p><blockquote>Vaxart：隐含上涨140%</blockquote></p><p>There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stock<b>Vaxart</b>(NASDAQ:VXRT).</p><p><blockquote>有近2000只小盘股和证券可供投资者选择。然而，华尔街专业人士认为，明年临床阶段生物技术股票的潜在回报率将很难超过140%<b>Vaxart</b>（纳斯达克：VXRT）。</blockquote></p><p>The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.</p><p><blockquote>Vaxart白手起家的故事将取决于该公司的冠状病毒疾病2019（COVID-19）治疗方案VXA-CoV2-1在临床研究中的表现。这种治疗方法的独特之处在于它是一种药片，而不是一种注射，可以在克服疫苗耐药性和给药方面发挥关键作用。毕竟，你不需要训练有素的医务人员来给药片服用。</blockquote></p><p>At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.</p><p><blockquote>2月初，Vaxart宣布VXA-CoV2-1在1期试验中迈出了积极的第一步。初步数据显示，它已达到所有主要和次要安全性和免疫原性终点。此外，有早期迹象表明它可能对新冠肺炎的原始和变异毒株有效。</blockquote></p><p>It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.</p><p><blockquote>现在判断Vaxart的口服COVID-19治疗是否会在中期或后期试验中取得成功还为时过早，但如果有效，它肯定会提供改变游戏规则的潜力。</blockquote></p><p><img src=\"https://static.tigerbbs.com/9c2902426a62a08435f7d40bec78432d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Harvest Health & Recreation: Implied upside of 90%</p><p><blockquote>Harvest Health&Recreation：隐含上涨90%</blockquote></p><p>With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)<b>Harvest Health & Recreation</b>(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.</p><p><blockquote>由于大麻预计将成为本十年的主要增长趋势，因此为美国多州运营商(MSO)设定较高的12个月价格目标也许并不奇怪<b>收获健康与娱乐</b>（场外交易代码：HRVSF）。如果华尔街的目标价准确，Harvest Health明年可能会上涨90%。</blockquote></p><p>Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.</p><p><blockquote>与大多数美国MSO不同，Harvest Health在2019年有点睁大了眼睛，过度扩张了自己。在终止了一些交易并筹集资金后，该公司现在有望在2021年实现盈利，预计全年销售额为3.8亿美元。就上下文而言，这意味着隐含销售额增长64%。</blockquote></p><p>Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.</p><p><blockquote>目前，该公司在五个州拥有37个运营零售点，核心关注四个市场：亚利桑那州、佛罗里达州、马里兰州和宾夕法尼亚州。尽管医用大麻仅合法，但佛罗里达州仍赚了很多钱，而宾夕法尼亚州是一个有限许可州，这应该会为该公司提供一定程度的竞争保护，因为该公司的目标是吞噬份额。但随着15家商店在其家乡亚利桑那州开业，大峡谷州代表着Harvest Health最大的机会。</blockquote></p><p>Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.</p><p><blockquote>尽管Harvest Health必须向投资者证明它已经克服了早期的运营失误，但它看起来将在2021年“走向绿色”。</blockquote></p><p><img src=\"https://static.tigerbbs.com/c13ce819ae0ba9b6755b8d61f6584bbc\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>EverQuote: Implied upside of 83%</p><p><blockquote>EverQuote：隐含上涨83%</blockquote></p><p>Another small-cap stock with serious upside potential is online insurance marketplace provider<b>EverQuote</b>(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.</p><p><blockquote>另一只具有巨大上涨潜力的小盘股是在线保险市场提供商<b>EverQuote</b>（纳斯达克：永远不会）。如果分析师准确的话，根据61.58美元的一致目标价，EverQuote明年的涨幅可能高达83%。</blockquote></p><p>Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.</p><p><blockquote>谈论任何与保险有关的事情通常足以让人昏昏欲睡。EverQuote旨在通过其在线市场改变这种状况，消费者可以快速轻松地从领先的保险提供商那里获得价格政策。据该公司称，五分之一的消费者最终会在其平台上购买保单，这表明其购物者往往有积极性。换句话说，保险公司通过委托EverQuote的市场获得了更大的广告收益。</blockquote></p><p></p><p>According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.</p><p><blockquote>据该公司称，未来四年数字保险广告支出预计将每年增长16%。相比之下，保险业的广告和分销总支出（包括数字支出）预计到2024年每年仅增长4%。EverQuote正在迎合保险业增长的最佳点。</blockquote></p><p>It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.</p><p><blockquote>它也是一家一直在向新的垂直行业转型的公司。尽管汽车保险一直是其市场的支柱，但近年来它增加了房屋、租房、健康和人寿保险选项。这些新的垂直行业的增长速度比传统的汽车政策快得多。</blockquote></p><p><img src=\"https://static.tigerbbs.com/f46d76c781cc47d68033914c1c794a63\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Jushi Holdings: Implied upside of 60%</p><p><blockquote>巨石控股：隐含上涨空间60%</blockquote></p><p>Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSO<b>Jushi Holdings</b>(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.</p><p><blockquote>以防你第一次没有抓住重点，华尔街对未来12个月的大多数美国大麻股票非常乐观。小盘股MSO<b>巨石控股</b>（场外交易代码：JUSHF）也不例外。如果巨石确实达到华尔街的目标价，它将为股东带来60%的收益。</blockquote></p><p>Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.</p><p><blockquote>Harvest Health专注于四个市场，而巨石则主要专注于三个市场：宾夕法尼亚州、伊利诺伊州和弗吉尼亚州。尽管它在大约六个州都有业务，但这三个州限制了它分配零售许可证的方式。宾夕法尼亚州和伊利诺伊州限制了允许的药房数量，而弗吉尼亚州则按司法管辖区分配许可证。结论是，巨石将有一个坚实的机会在这些州建立业务，同时面临最小的竞争。</blockquote></p><p>This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.</p><p><blockquote>这也是一家不害怕将资本投入使用的公司。自今年年初以来，该公司进行了一系列收购，包括扩大其在马萨诸塞州、俄亥俄州、宾夕法尼亚州和加利福尼亚州的零售或种植足迹。</blockquote></p><p>If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.</p><p><blockquote>如果您正在寻找另一个催化剂，请考虑一下高管和内部人士在最初筹集的2.5亿美元资金中贡献了约4500万美元。当内部人士和股东的利益一致时，我们经常会看到好事发生。</blockquote></p><p><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Inovio Pharmaceuticals: Implied upside of 128%</p><p><blockquote>Inovio Pharmaceuticals：隐含上涨128%</blockquote></p><p>Finally, clinical-stagebiotech stock<b>Inovio Pharmaceuticals</b>(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.</p><p><blockquote>最后，临床阶段生物技术股票<b>Inovio制药公司</b>（纳斯达克：INO）被认为具有显着的上涨空间。根据15.63美元的12个月目标价计算，Inovio的股价可能会上涨一倍以上。但这是我强烈反对华尔街的一个例子。</blockquote></p><p>For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.</p><p><blockquote>在过去一年的大部分时间里，Inovio股价飙升，因为人们期望它将成为开发COVID-19疫苗的领跑者之一。但尽管通过了1期研究，Inovio在美国的2/3期试验中遇到了部分临床搁置。上周，该公司宣布INO-4800治疗新冠肺炎的3期研究将在美国境外进行，美国国防部将停止资助该公司INO-4800的后期研究。</blockquote></p><p>There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.</p><p><blockquote>这里实际上有两个问题。首先，由于美国食品和药物管理局(FDA)的部分临床搁置，Inovio已经远远落后于同行，即使INO-4800在临床研究中取得成功，它也可能无法在全球COVID-19疫苗销售中占据有意义的比例。</blockquote></p><p>Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.</p><p><blockquote>其次，四十多年后，Inovio没有什么可展示的。尽管有大量正在进行的研究，但该公司的实验性治疗方法从未获得FDA的批准。这是一个非常明显的危险信号。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-04-27 19:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p>For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmark<b>S&P 500</b>has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.</p><p><blockquote>一年多来，投资者一直被华尔街史诗般的反弹宠坏了。在2020年第一季度短短33个日历日内损失了34%的价值后，该基准<b>标普500</b>自2020年3月23日触及熊市底部以来，截至上周末，股价已飙升87%。</blockquote></p><p>Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.</p><p><blockquote>尽管大盘股（市值至少100亿美元的公司）一直是这次反弹的明星，但华尔街认为小盘股（市值3亿至20亿美元）已经准备好大放异彩。小盘股通常风险更大，因为它们的运营模式未经时间考验或验证。但与更成熟的公司相比，它们通常可以提供更好的增长前景。</blockquote></p><p>Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.</p><p><blockquote>根据华尔街分析师一致的一年目标价，以下五只小盘股均提供60%至高达140%的上涨空间。</blockquote></p><p><img src=\"https://static.tigerbbs.com/e84aa34310d37f1ab30212f9dcf1bf0d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Vaxart: Implied upside of 140%</p><p><blockquote>Vaxart：隐含上涨140%</blockquote></p><p>There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stock<b>Vaxart</b>(NASDAQ:VXRT).</p><p><blockquote>有近2000只小盘股和证券可供投资者选择。然而，华尔街专业人士认为，明年临床阶段生物技术股票的潜在回报率将很难超过140%<b>Vaxart</b>（纳斯达克：VXRT）。</blockquote></p><p>The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.</p><p><blockquote>Vaxart白手起家的故事将取决于该公司的冠状病毒疾病2019（COVID-19）治疗方案VXA-CoV2-1在临床研究中的表现。这种治疗方法的独特之处在于它是一种药片，而不是一种注射，可以在克服疫苗耐药性和给药方面发挥关键作用。毕竟，你不需要训练有素的医务人员来给药片服用。</blockquote></p><p>At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.</p><p><blockquote>2月初，Vaxart宣布VXA-CoV2-1在1期试验中迈出了积极的第一步。初步数据显示，它已达到所有主要和次要安全性和免疫原性终点。此外，有早期迹象表明它可能对新冠肺炎的原始和变异毒株有效。</blockquote></p><p>It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.</p><p><blockquote>现在判断Vaxart的口服COVID-19治疗是否会在中期或后期试验中取得成功还为时过早，但如果有效，它肯定会提供改变游戏规则的潜力。</blockquote></p><p><img src=\"https://static.tigerbbs.com/9c2902426a62a08435f7d40bec78432d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Harvest Health & Recreation: Implied upside of 90%</p><p><blockquote>Harvest Health&Recreation：隐含上涨90%</blockquote></p><p>With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)<b>Harvest Health & Recreation</b>(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.</p><p><blockquote>由于大麻预计将成为本十年的主要增长趋势，因此为美国多州运营商(MSO)设定较高的12个月价格目标也许并不奇怪<b>收获健康与娱乐</b>（场外交易代码：HRVSF）。如果华尔街的目标价准确，Harvest Health明年可能会上涨90%。</blockquote></p><p>Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.</p><p><blockquote>与大多数美国MSO不同，Harvest Health在2019年有点睁大了眼睛，过度扩张了自己。在终止了一些交易并筹集资金后，该公司现在有望在2021年实现盈利，预计全年销售额为3.8亿美元。就上下文而言，这意味着隐含销售额增长64%。</blockquote></p><p>Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.</p><p><blockquote>目前，该公司在五个州拥有37个运营零售点，核心关注四个市场：亚利桑那州、佛罗里达州、马里兰州和宾夕法尼亚州。尽管医用大麻仅合法，但佛罗里达州仍赚了很多钱，而宾夕法尼亚州是一个有限许可州，这应该会为该公司提供一定程度的竞争保护，因为该公司的目标是吞噬份额。但随着15家商店在其家乡亚利桑那州开业，大峡谷州代表着Harvest Health最大的机会。</blockquote></p><p>Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.</p><p><blockquote>尽管Harvest Health必须向投资者证明它已经克服了早期的运营失误，但它看起来将在2021年“走向绿色”。</blockquote></p><p><img src=\"https://static.tigerbbs.com/c13ce819ae0ba9b6755b8d61f6584bbc\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>EverQuote: Implied upside of 83%</p><p><blockquote>EverQuote：隐含上涨83%</blockquote></p><p>Another small-cap stock with serious upside potential is online insurance marketplace provider<b>EverQuote</b>(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.</p><p><blockquote>另一只具有巨大上涨潜力的小盘股是在线保险市场提供商<b>EverQuote</b>（纳斯达克：永远不会）。如果分析师准确的话，根据61.58美元的一致目标价，EverQuote明年的涨幅可能高达83%。</blockquote></p><p>Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.</p><p><blockquote>谈论任何与保险有关的事情通常足以让人昏昏欲睡。EverQuote旨在通过其在线市场改变这种状况，消费者可以快速轻松地从领先的保险提供商那里获得价格政策。据该公司称，五分之一的消费者最终会在其平台上购买保单，这表明其购物者往往有积极性。换句话说，保险公司通过委托EverQuote的市场获得了更大的广告收益。</blockquote></p><p></p><p>According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.</p><p><blockquote>据该公司称，未来四年数字保险广告支出预计将每年增长16%。相比之下，保险业的广告和分销总支出（包括数字支出）预计到2024年每年仅增长4%。EverQuote正在迎合保险业增长的最佳点。</blockquote></p><p>It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.</p><p><blockquote>它也是一家一直在向新的垂直行业转型的公司。尽管汽车保险一直是其市场的支柱，但近年来它增加了房屋、租房、健康和人寿保险选项。这些新的垂直行业的增长速度比传统的汽车政策快得多。</blockquote></p><p><img src=\"https://static.tigerbbs.com/f46d76c781cc47d68033914c1c794a63\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Jushi Holdings: Implied upside of 60%</p><p><blockquote>巨石控股：隐含上涨空间60%</blockquote></p><p>Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSO<b>Jushi Holdings</b>(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.</p><p><blockquote>以防你第一次没有抓住重点，华尔街对未来12个月的大多数美国大麻股票非常乐观。小盘股MSO<b>巨石控股</b>（场外交易代码：JUSHF）也不例外。如果巨石确实达到华尔街的目标价，它将为股东带来60%的收益。</blockquote></p><p>Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.</p><p><blockquote>Harvest Health专注于四个市场，而巨石则主要专注于三个市场：宾夕法尼亚州、伊利诺伊州和弗吉尼亚州。尽管它在大约六个州都有业务，但这三个州限制了它分配零售许可证的方式。宾夕法尼亚州和伊利诺伊州限制了允许的药房数量，而弗吉尼亚州则按司法管辖区分配许可证。结论是，巨石将有一个坚实的机会在这些州建立业务，同时面临最小的竞争。</blockquote></p><p>This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.</p><p><blockquote>这也是一家不害怕将资本投入使用的公司。自今年年初以来，该公司进行了一系列收购，包括扩大其在马萨诸塞州、俄亥俄州、宾夕法尼亚州和加利福尼亚州的零售或种植足迹。</blockquote></p><p>If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.</p><p><blockquote>如果您正在寻找另一个催化剂，请考虑一下高管和内部人士在最初筹集的2.5亿美元资金中贡献了约4500万美元。当内部人士和股东的利益一致时，我们经常会看到好事发生。</blockquote></p><p><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Inovio Pharmaceuticals: Implied upside of 128%</p><p><blockquote>Inovio Pharmaceuticals：隐含上涨128%</blockquote></p><p>Finally, clinical-stagebiotech stock<b>Inovio Pharmaceuticals</b>(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.</p><p><blockquote>最后，临床阶段生物技术股票<b>Inovio制药公司</b>（纳斯达克：INO）被认为具有显着的上涨空间。根据15.63美元的12个月目标价计算，Inovio的股价可能会上涨一倍以上。但这是我强烈反对华尔街的一个例子。</blockquote></p><p>For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.</p><p><blockquote>在过去一年的大部分时间里，Inovio股价飙升，因为人们期望它将成为开发COVID-19疫苗的领跑者之一。但尽管通过了1期研究，Inovio在美国的2/3期试验中遇到了部分临床搁置。上周，该公司宣布INO-4800治疗新冠肺炎的3期研究将在美国境外进行，美国国防部将停止资助该公司INO-4800的后期研究。</blockquote></p><p>There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.</p><p><blockquote>这里实际上有两个问题。首先，由于美国食品和药物管理局(FDA)的部分临床搁置，Inovio已经远远落后于同行，即使INO-4800在临床研究中取得成功，它也可能无法在全球COVID-19疫苗销售中占据有意义的比例。</blockquote></p><p>Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.</p><p><blockquote>其次，四十多年后，Inovio没有什么可展示的。尽管有大量正在进行的研究，但该公司的实验性治疗方法从未获得FDA的批准。这是一个非常明显的危险信号。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/04/27/5-small-cap-stocks-60-to-140-upside-wall-street/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/27/5-small-cap-stocks-60-to-140-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112397012","content_text":"For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmarkS&P 500has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.IMAGE SOURCE: GETTY IMAGES.Vaxart: Implied upside of 140%There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stockVaxart(NASDAQ:VXRT).The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.IMAGE SOURCE: GETTY IMAGES.Harvest Health & Recreation: Implied upside of 90%With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)Harvest Health & Recreation(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.IMAGE SOURCE: GETTY IMAGES.EverQuote: Implied upside of 83%Another small-cap stock with serious upside potential is online insurance marketplace providerEverQuote(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.IMAGE SOURCE: GETTY IMAGES.Jushi Holdings: Implied upside of 60%Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSOJushi Holdings(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.IMAGE SOURCE: GETTY IMAGES.Inovio Pharmaceuticals: Implied upside of 128%Finally, clinical-stagebiotech stockInovio Pharmaceuticals(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377589110,"gmtCreate":1619535565330,"gmtModify":1634211959695,"author":{"id":"3580731839183444","authorId":"3580731839183444","name":"chantow","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580731839183444","authorIdStr":"3580731839183444"},"themes":[],"htmlText":"TESLA FTW","listText":"TESLA FTW","text":"TESLA FTW","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/377589110","repostId":"1190086074","repostType":4,"repost":{"id":"1190086074","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619480390,"share":"https://www.laohu8.com/m/news/1190086074?lang=zh_CN&edition=full","pubTime":"2021-04-27 07:39","market":"us","language":"en","title":"Tesla posts record net income of $438 million, revenue surges by 74%<blockquote>特斯拉净利润创纪录4.38亿美元营收暴增74%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190086074","media":"Tiger Newspress","summary":"Tesla reported record net income of $438 million during the quarter, as well as earnings of 93 cents per share on $10.39 billion in revenue.In its earnings release, the company said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.”On an earnings call, CEO Elon Musk said the delayed new version of the company’s Model S sedan will be deliv","content":"<p><b>KEY POINTS</b></p><p><blockquote><b>要点</b></blockquote></p><p><ul><li>Tesla reported record net income of $438 million during the quarter, as well as earnings of 93 cents per share on $10.39 billion in revenue.</li><li>In its earnings release, the company said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.”</li><li>On an earnings call, CEO Elon Musk said the delayed new version of the company’s Model S sedan will be delivered starting in May 2021, and Model X deliveries will begin in the third quarter of the year.</li></ul>Tesla reported first-quarter results after the bell on Monday. The company beat expectations handily, buoyed by sales of bitcoin and regulatory credits, but the stock dipped as much as 2.5% after hours as investors digested the numbers.</p><p><blockquote><ul><li>特斯拉报告本季度净利润达到创纪录的4.38亿美元，每股收益为93美分，营收为103.9亿美元。</li><li>该公司在财报中表示，通过“极快地转向新的微控制器，同时为新供应商制造的新芯片开发固件”，它已经度过了困扰汽车行业的芯片短缺问题。</li><li>在财报看涨期权上，首席执行官Elon Musk表示，该公司推迟的新版Model S轿车将于2021年5月开始交付，Model X将于今年第三季度开始交付。</li></ul>特斯拉周一盘后公布了第一季度业绩。在比特币销售和监管信贷的提振下，该公司轻松超出预期，但随着投资者消化这些数据，该股盘后下跌2.5%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/fec5c52f391c1077b749edc13b7b3417\" tg-width=\"1302\" tg-height=\"833\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Here’s how the company fared in the quarter, compared with analyst estimates compiled by Refinitiv:</p><p><blockquote>以下是该公司本季度的表现，与Refinitiv编制的分析师预期相比：</blockquote></p><p><ul><li><b>Earnings:</b>93 cents per share vs. 79 cents per share expected</li><li><b>Revenue:</b>$10.39 billion vs. $10.29 billion expected, up 74% from a year ago</li></ul>Net profit reached a quarterly record of $438 million on a GAAP basis, and the company recorded $518 million in revenue from sales of regulatory credits during the period. It also recorded a $101 million positive impact from sales of bitcoin during the quarter.</p><p><blockquote><ul><li><b>收益：</b>每股93美分，预期每股79美分</li><li><b>收入：</b>103.9亿美元，预期为102.9亿美元，同比增长74%</li></ul>按GAAP计算，净利润达到季度创纪录的4.38亿美元，该公司在此期间从监管信贷销售中获得了5.18亿美元的收入。本季度比特币销售还带来了1.01亿美元的积极影响。</blockquote></p><p><img src=\"https://static.tigerbbs.com/107ab1e725bed375ea106bdf3024ec6a\" tg-width=\"1910\" tg-height=\"1097\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>CEO Elon Musk’s electric vehicle business reported in the first quarter vehicle deliveries of 184,800 Model 3 and Model Y cars, beating expectations and setting a record for Tesla. However, the company also said it produced none of its higher-end Model S sedans or Model X SUVs for the period ending March. It delivered2,020 older Model S sedans and Model X SUVs from inventory.</p><p><blockquote>首席执行官Elon Musk的电动汽车业务报告称，第一季度Model 3和Model Y汽车交付量为18.48万辆，超出预期，创下了特斯拉的纪录。不过，该公司还表示，截至3月份，该公司没有生产任何高端Model S轿车或Model X SUV。它从库存中交付了2,020辆旧款Model S轿车和Model X SUV。</blockquote></p><p>On Monday’s earnings call, Musk said the new version of the company’s Model S sedans will finally be delivered to customers starting in May 2021, with Model X deliveries to begin in the third quarter of the year. Musk and CFO Zachary Kirkhorn both said supply chain issues are likely to remain a challenge for Tesla this year.</p><p><blockquote>在周一的财报看涨期权上，Musk表示，该公司新版Model S轿车最终将于2021年5月开始向客户交付，Model X将于今年第三季度开始交付。Musk和CFO Zachary Kirkhorn均表示，供应链问题可能仍是特斯拉今年面临的挑战。</blockquote></p><p>In January 2021 (during a fourth-quarter 2020 earnings update) Musk had said that the Model S Plaid was already in production would be delivered starting in February 2021. But he admitted on Monday, “There were more challenges than expected,” in producing the refreshed version of these vehicles. He did not elaborate.</p><p><blockquote>2021年1月（在2020年第四季度财报更新期间），马斯克曾表示，Model S Plaid已经投入生产，将于2021年2月开始交付。但他周一承认，在生产这些车辆的更新版本时，“存在比预期更多的挑战”。他没有详细说明。</blockquote></p><p>Tesla is now aiming to produce 2,000 Model S and X vehicles per week later this year.</p><p><blockquote>特斯拉目前的目标是在今年晚些时候每周生产2,000辆Model S和X汽车。</blockquote></p><p>The company said Monday it expects more than 50% vehicle delivery growth in 2021 overall, which implies minimum deliveries around 750,000 vehicles this year.</p><p><blockquote>该公司周一表示，预计2021年汽车交付量总体增长将超过50%，这意味着今年的最低交付量约为75万辆。</blockquote></p><p>The fact Tesla grew vehicle unit sales by more than 100% year over year but grew service centers by only 28% and its mobile service fleet by only 22% explains why some Tesla customers face frustratingly long wait times for repairs. Service expansion is not keeping pace with the volume of vehicles sold.</p><p><blockquote>事实上，特斯拉的汽车销量同比增长超过100%，但服务中心仅增长28%，移动服务车队仅增长22%，这解释了为什么一些特斯拉客户面临令人沮丧的漫长维修等待时间。服务扩张跟不上车辆销量的步伐。</blockquote></p><p>Tesla said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.” It did not disclose the names of its new suppliers.</p><p><blockquote>特斯拉表示，它通过“极快地转向新的微控制器，同时为新供应商制造的新芯片开发固件”，部分克服了困扰汽车行业的芯片短缺问题。它没有透露新供应商的名称。</blockquote></p><p>It also reiterated Musk’s frequent claim that cameras, not radar, are a better path toward autonomous vehicles. “Our AI-based software architecture has been increasingly reliant on cameras, to the point where radar is becoming unnecessary earlier than expected. As a result, our FSD [Full Self-Driving] team is fully focused on evolving to a vision-based autonomous system and we are nearly ready to switch the US market to Tesla Vision,” the company said in its earnings release.</p><p><blockquote>它还重申了马斯克经常声称的摄像头而不是雷达是自动驾驶汽车的更好途径。“我们基于人工智能的软件架构越来越依赖摄像头，以至于雷达比预期更早变得不必要。因此，我们的FSD（全自动驾驶）团队完全专注于向基于视觉的自动驾驶系统发展，我们几乎准备好将美国市场转向特斯拉视觉，”该公司在财报中表示。</blockquote></p><p>Revenue for its energy generation and storage business nearly doubled for Tesla versus the same period in 2020, when Musk said Covid, then an emerging pandemic, had slowed its energy business to a crawl. But energy revenue declined from $787 million in the fourth quarter to $595 million in the first quarter of 2021.</p><p><blockquote>与2020年同期相比，特斯拉能源发电和存储业务的收入几乎翻了一番，当时马斯克表示，当时新冠疫情是一种新兴流行病，导致其能源业务放缓。但能源收入从第四季度的7.87亿美元下降至2021年第一季度的5.95亿美元。</blockquote></p><p>Recently, Tesla increased prices for its solar rooftops by 50%, and now requires anyone ordering solar photovoltaics (including Tesla solar roof tiles) to also order the Powerwall, Tesla’s home energy storage system. The sudden price change applied retroactively to some vexed customers.</p><p><blockquote>最近，特斯拉将其太阳能屋顶的价格提高了50%，现在要求任何订购太阳能光伏（包括特斯拉太阳能屋顶瓦片）的人也必须订购特斯拉的家庭储能系统Powerwall。突然的价格变化追溯适用于一些恼怒的顾客。</blockquote></p><p>Musk said on the Q1 2021 call that he is aiming for homes with solar rooftops and batteries from Tesla to function as a “giant distributed utility” that can help incumbent electrical utilities supply customers with all the electricity they need as demand and extreme weather events increase.</p><p><blockquote>马斯克在2021年第一季度看涨期权上表示，他的目标是让拥有太阳能屋顶和特斯拉电池的家庭成为“巨型分布式公用事业公司”，可以帮助现有电力公司在需求和极端天气事件增加时为客户提供所需的所有电力。</blockquote></p><p></p><p>Executives did not say how they would change their production or mix of battery cells from suppliers in order to make a higher volume of vehicles and energy storage products in 2021.</p><p><blockquote>高管们没有透露他们将如何改变供应商的电池生产或组合，以便在2021年生产更多的汽车和储能产品。</blockquote></p><p>Musk said the company’s 4680 cells, which it developed independently and makes at a pilot plant in Fremont, California, are not yet reliable enough to be shipped in Tesla vehicles. He said Tesla would probably “achieve volume production” of these cells in 12 to 18 months.</p><p><blockquote>Musk表示，该公司自主开发并在加州Fremont的一家试点工厂生产的4680电池还不够可靠，无法用特斯拉汽车运输。他表示，特斯拉可能会在12至18个月内“实现批量生产”这些电池。</blockquote></p><p>The company revealed in February it purchased $1.5 billion in bitcoin and would potentially invest in other cryptocurrencies in the future. By April, bitcoin rose to record levels before pulling back. In its statement of cash flows, Tesla revealed that it had sold $272 million worth of “digital assets,” presumably bitcoin, during the quarter.</p><p><blockquote>该公司在2月份透露，它购买了15亿美元的比特币，并可能在未来投资其他加密货币。到4月份，比特币升至创纪录水平，然后回落。特斯拉在其现金流量表中透露，该公司在本季度出售了价值2.72亿美元的“数字资产”，可能是比特币。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla posts record net income of $438 million, revenue surges by 74%<blockquote>特斯拉净利润创纪录4.38亿美元营收暴增74%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla posts record net income of $438 million, revenue surges by 74%<blockquote>特斯拉净利润创纪录4.38亿美元营收暴增74%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-04-27 07:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>KEY POINTS</b></p><p><blockquote><b>要点</b></blockquote></p><p><ul><li>Tesla reported record net income of $438 million during the quarter, as well as earnings of 93 cents per share on $10.39 billion in revenue.</li><li>In its earnings release, the company said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.”</li><li>On an earnings call, CEO Elon Musk said the delayed new version of the company’s Model S sedan will be delivered starting in May 2021, and Model X deliveries will begin in the third quarter of the year.</li></ul>Tesla reported first-quarter results after the bell on Monday. The company beat expectations handily, buoyed by sales of bitcoin and regulatory credits, but the stock dipped as much as 2.5% after hours as investors digested the numbers.</p><p><blockquote><ul><li>特斯拉报告本季度净利润达到创纪录的4.38亿美元，每股收益为93美分，营收为103.9亿美元。</li><li>该公司在财报中表示，通过“极快地转向新的微控制器，同时为新供应商制造的新芯片开发固件”，它已经度过了困扰汽车行业的芯片短缺问题。</li><li>在财报看涨期权上，首席执行官Elon Musk表示，该公司推迟的新版Model S轿车将于2021年5月开始交付，Model X将于今年第三季度开始交付。</li></ul>特斯拉周一盘后公布了第一季度业绩。在比特币销售和监管信贷的提振下，该公司轻松超出预期，但随着投资者消化这些数据，该股盘后下跌2.5%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/fec5c52f391c1077b749edc13b7b3417\" tg-width=\"1302\" tg-height=\"833\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Here’s how the company fared in the quarter, compared with analyst estimates compiled by Refinitiv:</p><p><blockquote>以下是该公司本季度的表现，与Refinitiv编制的分析师预期相比：</blockquote></p><p><ul><li><b>Earnings:</b>93 cents per share vs. 79 cents per share expected</li><li><b>Revenue:</b>$10.39 billion vs. $10.29 billion expected, up 74% from a year ago</li></ul>Net profit reached a quarterly record of $438 million on a GAAP basis, and the company recorded $518 million in revenue from sales of regulatory credits during the period. It also recorded a $101 million positive impact from sales of bitcoin during the quarter.</p><p><blockquote><ul><li><b>收益：</b>每股93美分，预期每股79美分</li><li><b>收入：</b>103.9亿美元，预期为102.9亿美元，同比增长74%</li></ul>按GAAP计算，净利润达到季度创纪录的4.38亿美元，该公司在此期间从监管信贷销售中获得了5.18亿美元的收入。本季度比特币销售还带来了1.01亿美元的积极影响。</blockquote></p><p><img src=\"https://static.tigerbbs.com/107ab1e725bed375ea106bdf3024ec6a\" tg-width=\"1910\" tg-height=\"1097\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>CEO Elon Musk’s electric vehicle business reported in the first quarter vehicle deliveries of 184,800 Model 3 and Model Y cars, beating expectations and setting a record for Tesla. However, the company also said it produced none of its higher-end Model S sedans or Model X SUVs for the period ending March. It delivered2,020 older Model S sedans and Model X SUVs from inventory.</p><p><blockquote>首席执行官Elon Musk的电动汽车业务报告称，第一季度Model 3和Model Y汽车交付量为18.48万辆，超出预期，创下了特斯拉的纪录。不过，该公司还表示，截至3月份，该公司没有生产任何高端Model S轿车或Model X SUV。它从库存中交付了2,020辆旧款Model S轿车和Model X SUV。</blockquote></p><p>On Monday’s earnings call, Musk said the new version of the company’s Model S sedans will finally be delivered to customers starting in May 2021, with Model X deliveries to begin in the third quarter of the year. Musk and CFO Zachary Kirkhorn both said supply chain issues are likely to remain a challenge for Tesla this year.</p><p><blockquote>在周一的财报看涨期权上，Musk表示，该公司新版Model S轿车最终将于2021年5月开始向客户交付，Model X将于今年第三季度开始交付。Musk和CFO Zachary Kirkhorn均表示，供应链问题可能仍是特斯拉今年面临的挑战。</blockquote></p><p>In January 2021 (during a fourth-quarter 2020 earnings update) Musk had said that the Model S Plaid was already in production would be delivered starting in February 2021. But he admitted on Monday, “There were more challenges than expected,” in producing the refreshed version of these vehicles. He did not elaborate.</p><p><blockquote>2021年1月（在2020年第四季度财报更新期间），马斯克曾表示，Model S Plaid已经投入生产，将于2021年2月开始交付。但他周一承认，在生产这些车辆的更新版本时，“存在比预期更多的挑战”。他没有详细说明。</blockquote></p><p>Tesla is now aiming to produce 2,000 Model S and X vehicles per week later this year.</p><p><blockquote>特斯拉目前的目标是在今年晚些时候每周生产2,000辆Model S和X汽车。</blockquote></p><p>The company said Monday it expects more than 50% vehicle delivery growth in 2021 overall, which implies minimum deliveries around 750,000 vehicles this year.</p><p><blockquote>该公司周一表示，预计2021年汽车交付量总体增长将超过50%，这意味着今年的最低交付量约为75万辆。</blockquote></p><p>The fact Tesla grew vehicle unit sales by more than 100% year over year but grew service centers by only 28% and its mobile service fleet by only 22% explains why some Tesla customers face frustratingly long wait times for repairs. Service expansion is not keeping pace with the volume of vehicles sold.</p><p><blockquote>事实上，特斯拉的汽车销量同比增长超过100%，但服务中心仅增长28%，移动服务车队仅增长22%，这解释了为什么一些特斯拉客户面临令人沮丧的漫长维修等待时间。服务扩张跟不上车辆销量的步伐。</blockquote></p><p>Tesla said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.” It did not disclose the names of its new suppliers.</p><p><blockquote>特斯拉表示，它通过“极快地转向新的微控制器，同时为新供应商制造的新芯片开发固件”，部分克服了困扰汽车行业的芯片短缺问题。它没有透露新供应商的名称。</blockquote></p><p>It also reiterated Musk’s frequent claim that cameras, not radar, are a better path toward autonomous vehicles. “Our AI-based software architecture has been increasingly reliant on cameras, to the point where radar is becoming unnecessary earlier than expected. As a result, our FSD [Full Self-Driving] team is fully focused on evolving to a vision-based autonomous system and we are nearly ready to switch the US market to Tesla Vision,” the company said in its earnings release.</p><p><blockquote>它还重申了马斯克经常声称的摄像头而不是雷达是自动驾驶汽车的更好途径。“我们基于人工智能的软件架构越来越依赖摄像头，以至于雷达比预期更早变得不必要。因此，我们的FSD（全自动驾驶）团队完全专注于向基于视觉的自动驾驶系统发展，我们几乎准备好将美国市场转向特斯拉视觉，”该公司在财报中表示。</blockquote></p><p>Revenue for its energy generation and storage business nearly doubled for Tesla versus the same period in 2020, when Musk said Covid, then an emerging pandemic, had slowed its energy business to a crawl. But energy revenue declined from $787 million in the fourth quarter to $595 million in the first quarter of 2021.</p><p><blockquote>与2020年同期相比，特斯拉能源发电和存储业务的收入几乎翻了一番，当时马斯克表示，当时新冠疫情是一种新兴流行病，导致其能源业务放缓。但能源收入从第四季度的7.87亿美元下降至2021年第一季度的5.95亿美元。</blockquote></p><p>Recently, Tesla increased prices for its solar rooftops by 50%, and now requires anyone ordering solar photovoltaics (including Tesla solar roof tiles) to also order the Powerwall, Tesla’s home energy storage system. The sudden price change applied retroactively to some vexed customers.</p><p><blockquote>最近，特斯拉将其太阳能屋顶的价格提高了50%，现在要求任何订购太阳能光伏（包括特斯拉太阳能屋顶瓦片）的人也必须订购特斯拉的家庭储能系统Powerwall。突然的价格变化追溯适用于一些恼怒的顾客。</blockquote></p><p>Musk said on the Q1 2021 call that he is aiming for homes with solar rooftops and batteries from Tesla to function as a “giant distributed utility” that can help incumbent electrical utilities supply customers with all the electricity they need as demand and extreme weather events increase.</p><p><blockquote>马斯克在2021年第一季度看涨期权上表示，他的目标是让拥有太阳能屋顶和特斯拉电池的家庭成为“巨型分布式公用事业公司”，可以帮助现有电力公司在需求和极端天气事件增加时为客户提供所需的所有电力。</blockquote></p><p></p><p>Executives did not say how they would change their production or mix of battery cells from suppliers in order to make a higher volume of vehicles and energy storage products in 2021.</p><p><blockquote>高管们没有透露他们将如何改变供应商的电池生产或组合，以便在2021年生产更多的汽车和储能产品。</blockquote></p><p>Musk said the company’s 4680 cells, which it developed independently and makes at a pilot plant in Fremont, California, are not yet reliable enough to be shipped in Tesla vehicles. He said Tesla would probably “achieve volume production” of these cells in 12 to 18 months.</p><p><blockquote>Musk表示，该公司自主开发并在加州Fremont的一家试点工厂生产的4680电池还不够可靠，无法用特斯拉汽车运输。他表示，特斯拉可能会在12至18个月内“实现批量生产”这些电池。</blockquote></p><p>The company revealed in February it purchased $1.5 billion in bitcoin and would potentially invest in other cryptocurrencies in the future. By April, bitcoin rose to record levels before pulling back. In its statement of cash flows, Tesla revealed that it had sold $272 million worth of “digital assets,” presumably bitcoin, during the quarter.</p><p><blockquote>该公司在2月份透露，它购买了15亿美元的比特币，并可能在未来投资其他加密货币。到4月份，比特币升至创纪录水平，然后回落。特斯拉在其现金流量表中透露，该公司在本季度出售了价值2.72亿美元的“数字资产”，可能是比特币。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190086074","content_text":"KEY POINTSTesla reported record net income of $438 million during the quarter, as well as earnings of 93 cents per share on $10.39 billion in revenue.In its earnings release, the company said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.”On an earnings call, CEO Elon Musk said the delayed new version of the company’s Model S sedan will be delivered starting in May 2021, and Model X deliveries will begin in the third quarter of the year.Tesla reported first-quarter results after the bell on Monday. The company beat expectations handily, buoyed by sales of bitcoin and regulatory credits, but the stock dipped as much as 2.5% after hours as investors digested the numbers.Here’s how the company fared in the quarter, compared with analyst estimates compiled by Refinitiv:Earnings:93 cents per share vs. 79 cents per share expectedRevenue:$10.39 billion vs. $10.29 billion expected, up 74% from a year agoNet profit reached a quarterly record of $438 million on a GAAP basis, and the company recorded $518 million in revenue from sales of regulatory credits during the period. It also recorded a $101 million positive impact from sales of bitcoin during the quarter.CEO Elon Musk’s electric vehicle business reported in the first quarter vehicle deliveries of 184,800 Model 3 and Model Y cars, beating expectations and setting a record for Tesla. However, the company also said it produced none of its higher-end Model S sedans or Model X SUVs for the period ending March. It delivered2,020 older Model S sedans and Model X SUVs from inventory.On Monday’s earnings call, Musk said the new version of the company’s Model S sedans will finally be delivered to customers starting in May 2021, with Model X deliveries to begin in the third quarter of the year. Musk and CFO Zachary Kirkhorn both said supply chain issues are likely to remain a challenge for Tesla this year.In January 2021 (during a fourth-quarter 2020 earnings update) Musk had said that the Model S Plaid was already in production would be delivered starting in February 2021. But he admitted on Monday, “There were more challenges than expected,” in producing the refreshed version of these vehicles. He did not elaborate.Tesla is now aiming to produce 2,000 Model S and X vehicles per week later this year.The company said Monday it expects more than 50% vehicle delivery growth in 2021 overall, which implies minimum deliveries around 750,000 vehicles this year.The fact Tesla grew vehicle unit sales by more than 100% year over year but grew service centers by only 28% and its mobile service fleet by only 22% explains why some Tesla customers face frustratingly long wait times for repairs. Service expansion is not keeping pace with the volume of vehicles sold.Tesla said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.” It did not disclose the names of its new suppliers.It also reiterated Musk’s frequent claim that cameras, not radar, are a better path toward autonomous vehicles. “Our AI-based software architecture has been increasingly reliant on cameras, to the point where radar is becoming unnecessary earlier than expected. As a result, our FSD [Full Self-Driving] team is fully focused on evolving to a vision-based autonomous system and we are nearly ready to switch the US market to Tesla Vision,” the company said in its earnings release.Revenue for its energy generation and storage business nearly doubled for Tesla versus the same period in 2020, when Musk said Covid, then an emerging pandemic, had slowed its energy business to a crawl. But energy revenue declined from $787 million in the fourth quarter to $595 million in the first quarter of 2021.Recently, Tesla increased prices for its solar rooftops by 50%, and now requires anyone ordering solar photovoltaics (including Tesla solar roof tiles) to also order the Powerwall, Tesla’s home energy storage system. The sudden price change applied retroactively to some vexed customers.Musk said on the Q1 2021 call that he is aiming for homes with solar rooftops and batteries from Tesla to function as a “giant distributed utility” that can help incumbent electrical utilities supply customers with all the electricity they need as demand and extreme weather events increase.Executives did not say how they would change their production or mix of battery cells from suppliers in order to make a higher volume of vehicles and energy storage products in 2021.Musk said the company’s 4680 cells, which it developed independently and makes at a pilot plant in Fremont, California, are not yet reliable enough to be shipped in Tesla vehicles. He said Tesla would probably “achieve volume production” of these cells in 12 to 18 months.The company revealed in February it purchased $1.5 billion in bitcoin and would potentially invest in other cryptocurrencies in the future. By April, bitcoin rose to record levels before pulling back. In its statement of cash flows, Tesla revealed that it had sold $272 million worth of “digital assets,” presumably bitcoin, during the quarter.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":3264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":377581011,"gmtCreate":1619535680733,"gmtModify":1634211958870,"author":{"id":"3580731839183444","authorId":"3580731839183444","name":"chantow","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580731839183444","authorIdStr":"3580731839183444"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/377581011","repostId":"1112397012","repostType":4,"repost":{"id":"1112397012","kind":"news","pubTimestamp":1619521537,"share":"https://www.laohu8.com/m/news/1112397012?lang=zh_CN&edition=full","pubTime":"2021-04-27 19:05","market":"us","language":"en","title":"5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1112397012","media":"Motley Fool","summary":"For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% ","content":"<p>For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmark<b>S&P 500</b>has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.</p><p><blockquote>一年多来，投资者一直被华尔街史诗般的反弹宠坏了。在2020年第一季度短短33个日历日内损失了34%的价值后，该基准<b>标普500</b>自2020年3月23日触及熊市底部以来，截至上周末，股价已飙升87%。</blockquote></p><p>Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.</p><p><blockquote>尽管大盘股（市值至少100亿美元的公司）一直是这次反弹的明星，但华尔街认为小盘股（市值3亿至20亿美元）已经准备好大放异彩。小盘股通常风险更大，因为它们的运营模式未经时间考验或验证。但与更成熟的公司相比，它们通常可以提供更好的增长前景。</blockquote></p><p>Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.</p><p><blockquote>根据华尔街分析师一致的一年目标价，以下五只小盘股均提供60%至高达140%的上涨空间。</blockquote></p><p><img src=\"https://static.tigerbbs.com/e84aa34310d37f1ab30212f9dcf1bf0d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Vaxart: Implied upside of 140%</p><p><blockquote>Vaxart：隐含上涨140%</blockquote></p><p>There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stock<b>Vaxart</b>(NASDAQ:VXRT).</p><p><blockquote>有近2000只小盘股和证券可供投资者选择。然而，华尔街专业人士认为，明年临床阶段生物技术股票的潜在回报率将很难超过140%<b>Vaxart</b>（纳斯达克：VXRT）。</blockquote></p><p>The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.</p><p><blockquote>Vaxart白手起家的故事将取决于该公司的冠状病毒疾病2019（COVID-19）治疗方案VXA-CoV2-1在临床研究中的表现。这种治疗方法的独特之处在于它是一种药片，而不是一种注射，可以在克服疫苗耐药性和给药方面发挥关键作用。毕竟，你不需要训练有素的医务人员来给药片服用。</blockquote></p><p>At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.</p><p><blockquote>2月初，Vaxart宣布VXA-CoV2-1在1期试验中迈出了积极的第一步。初步数据显示，它已达到所有主要和次要安全性和免疫原性终点。此外，有早期迹象表明它可能对新冠肺炎的原始和变异毒株有效。</blockquote></p><p>It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.</p><p><blockquote>现在判断Vaxart的口服COVID-19治疗是否会在中期或后期试验中取得成功还为时过早，但如果有效，它肯定会提供改变游戏规则的潜力。</blockquote></p><p><img src=\"https://static.tigerbbs.com/9c2902426a62a08435f7d40bec78432d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Harvest Health & Recreation: Implied upside of 90%</p><p><blockquote>Harvest Health&Recreation：隐含上涨90%</blockquote></p><p>With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)<b>Harvest Health & Recreation</b>(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.</p><p><blockquote>由于大麻预计将成为本十年的主要增长趋势，因此为美国多州运营商(MSO)设定较高的12个月价格目标也许并不奇怪<b>收获健康与娱乐</b>（场外交易代码：HRVSF）。如果华尔街的目标价准确，Harvest Health明年可能会上涨90%。</blockquote></p><p>Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.</p><p><blockquote>与大多数美国MSO不同，Harvest Health在2019年有点睁大了眼睛，过度扩张了自己。在终止了一些交易并筹集资金后，该公司现在有望在2021年实现盈利，预计全年销售额为3.8亿美元。就上下文而言，这意味着隐含销售额增长64%。</blockquote></p><p>Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.</p><p><blockquote>目前，该公司在五个州拥有37个运营零售点，核心关注四个市场：亚利桑那州、佛罗里达州、马里兰州和宾夕法尼亚州。尽管医用大麻仅合法，但佛罗里达州仍赚了很多钱，而宾夕法尼亚州是一个有限许可州，这应该会为该公司提供一定程度的竞争保护，因为该公司的目标是吞噬份额。但随着15家商店在其家乡亚利桑那州开业，大峡谷州代表着Harvest Health最大的机会。</blockquote></p><p>Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.</p><p><blockquote>尽管Harvest Health必须向投资者证明它已经克服了早期的运营失误，但它看起来将在2021年“走向绿色”。</blockquote></p><p><img src=\"https://static.tigerbbs.com/c13ce819ae0ba9b6755b8d61f6584bbc\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>EverQuote: Implied upside of 83%</p><p><blockquote>EverQuote：隐含上涨83%</blockquote></p><p>Another small-cap stock with serious upside potential is online insurance marketplace provider<b>EverQuote</b>(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.</p><p><blockquote>另一只具有巨大上涨潜力的小盘股是在线保险市场提供商<b>EverQuote</b>（纳斯达克：永远不会）。如果分析师准确的话，根据61.58美元的一致目标价，EverQuote明年的涨幅可能高达83%。</blockquote></p><p>Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.</p><p><blockquote>谈论任何与保险有关的事情通常足以让人昏昏欲睡。EverQuote旨在通过其在线市场改变这种状况，消费者可以快速轻松地从领先的保险提供商那里获得价格政策。据该公司称，五分之一的消费者最终会在其平台上购买保单，这表明其购物者往往有积极性。换句话说，保险公司通过委托EverQuote的市场获得了更大的广告收益。</blockquote></p><p></p><p>According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.</p><p><blockquote>据该公司称，未来四年数字保险广告支出预计将每年增长16%。相比之下，保险业的广告和分销总支出（包括数字支出）预计到2024年每年仅增长4%。EverQuote正在迎合保险业增长的最佳点。</blockquote></p><p>It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.</p><p><blockquote>它也是一家一直在向新的垂直行业转型的公司。尽管汽车保险一直是其市场的支柱，但近年来它增加了房屋、租房、健康和人寿保险选项。这些新的垂直行业的增长速度比传统的汽车政策快得多。</blockquote></p><p><img src=\"https://static.tigerbbs.com/f46d76c781cc47d68033914c1c794a63\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Jushi Holdings: Implied upside of 60%</p><p><blockquote>巨石控股：隐含上涨空间60%</blockquote></p><p>Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSO<b>Jushi Holdings</b>(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.</p><p><blockquote>以防你第一次没有抓住重点，华尔街对未来12个月的大多数美国大麻股票非常乐观。小盘股MSO<b>巨石控股</b>（场外交易代码：JUSHF）也不例外。如果巨石确实达到华尔街的目标价，它将为股东带来60%的收益。</blockquote></p><p>Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.</p><p><blockquote>Harvest Health专注于四个市场，而巨石则主要专注于三个市场：宾夕法尼亚州、伊利诺伊州和弗吉尼亚州。尽管它在大约六个州都有业务，但这三个州限制了它分配零售许可证的方式。宾夕法尼亚州和伊利诺伊州限制了允许的药房数量，而弗吉尼亚州则按司法管辖区分配许可证。结论是，巨石将有一个坚实的机会在这些州建立业务，同时面临最小的竞争。</blockquote></p><p>This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.</p><p><blockquote>这也是一家不害怕将资本投入使用的公司。自今年年初以来，该公司进行了一系列收购，包括扩大其在马萨诸塞州、俄亥俄州、宾夕法尼亚州和加利福尼亚州的零售或种植足迹。</blockquote></p><p>If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.</p><p><blockquote>如果您正在寻找另一个催化剂，请考虑一下高管和内部人士在最初筹集的2.5亿美元资金中贡献了约4500万美元。当内部人士和股东的利益一致时，我们经常会看到好事发生。</blockquote></p><p><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Inovio Pharmaceuticals: Implied upside of 128%</p><p><blockquote>Inovio Pharmaceuticals：隐含上涨128%</blockquote></p><p>Finally, clinical-stagebiotech stock<b>Inovio Pharmaceuticals</b>(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.</p><p><blockquote>最后，临床阶段生物技术股票<b>Inovio制药公司</b>（纳斯达克：INO）被认为具有显着的上涨空间。根据15.63美元的12个月目标价计算，Inovio的股价可能会上涨一倍以上。但这是我强烈反对华尔街的一个例子。</blockquote></p><p>For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.</p><p><blockquote>在过去一年的大部分时间里，Inovio股价飙升，因为人们期望它将成为开发COVID-19疫苗的领跑者之一。但尽管通过了1期研究，Inovio在美国的2/3期试验中遇到了部分临床搁置。上周，该公司宣布INO-4800治疗新冠肺炎的3期研究将在美国境外进行，美国国防部将停止资助该公司INO-4800的后期研究。</blockquote></p><p>There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.</p><p><blockquote>这里实际上有两个问题。首先，由于美国食品和药物管理局(FDA)的部分临床搁置，Inovio已经远远落后于同行，即使INO-4800在临床研究中取得成功，它也可能无法在全球COVID-19疫苗销售中占据有意义的比例。</blockquote></p><p>Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.</p><p><blockquote>其次，四十多年后，Inovio没有什么可展示的。尽管有大量正在进行的研究，但该公司的实验性治疗方法从未获得FDA的批准。这是一个非常明显的危险信号。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称5只小盘股上涨60%至140%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-04-27 19:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p>For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmark<b>S&P 500</b>has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.</p><p><blockquote>一年多来，投资者一直被华尔街史诗般的反弹宠坏了。在2020年第一季度短短33个日历日内损失了34%的价值后，该基准<b>标普500</b>自2020年3月23日触及熊市底部以来，截至上周末，股价已飙升87%。</blockquote></p><p>Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.</p><p><blockquote>尽管大盘股（市值至少100亿美元的公司）一直是这次反弹的明星，但华尔街认为小盘股（市值3亿至20亿美元）已经准备好大放异彩。小盘股通常风险更大，因为它们的运营模式未经时间考验或验证。但与更成熟的公司相比，它们通常可以提供更好的增长前景。</blockquote></p><p>Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.</p><p><blockquote>根据华尔街分析师一致的一年目标价，以下五只小盘股均提供60%至高达140%的上涨空间。</blockquote></p><p><img src=\"https://static.tigerbbs.com/e84aa34310d37f1ab30212f9dcf1bf0d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Vaxart: Implied upside of 140%</p><p><blockquote>Vaxart：隐含上涨140%</blockquote></p><p>There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stock<b>Vaxart</b>(NASDAQ:VXRT).</p><p><blockquote>有近2000只小盘股和证券可供投资者选择。然而，华尔街专业人士认为，明年临床阶段生物技术股票的潜在回报率将很难超过140%<b>Vaxart</b>（纳斯达克：VXRT）。</blockquote></p><p>The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.</p><p><blockquote>Vaxart白手起家的故事将取决于该公司的冠状病毒疾病2019（COVID-19）治疗方案VXA-CoV2-1在临床研究中的表现。这种治疗方法的独特之处在于它是一种药片，而不是一种注射，可以在克服疫苗耐药性和给药方面发挥关键作用。毕竟，你不需要训练有素的医务人员来给药片服用。</blockquote></p><p>At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.</p><p><blockquote>2月初，Vaxart宣布VXA-CoV2-1在1期试验中迈出了积极的第一步。初步数据显示，它已达到所有主要和次要安全性和免疫原性终点。此外，有早期迹象表明它可能对新冠肺炎的原始和变异毒株有效。</blockquote></p><p>It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.</p><p><blockquote>现在判断Vaxart的口服COVID-19治疗是否会在中期或后期试验中取得成功还为时过早，但如果有效，它肯定会提供改变游戏规则的潜力。</blockquote></p><p><img src=\"https://static.tigerbbs.com/9c2902426a62a08435f7d40bec78432d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Harvest Health & Recreation: Implied upside of 90%</p><p><blockquote>Harvest Health&Recreation：隐含上涨90%</blockquote></p><p>With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)<b>Harvest Health & Recreation</b>(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.</p><p><blockquote>由于大麻预计将成为本十年的主要增长趋势，因此为美国多州运营商(MSO)设定较高的12个月价格目标也许并不奇怪<b>收获健康与娱乐</b>（场外交易代码：HRVSF）。如果华尔街的目标价准确，Harvest Health明年可能会上涨90%。</blockquote></p><p>Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.</p><p><blockquote>与大多数美国MSO不同，Harvest Health在2019年有点睁大了眼睛，过度扩张了自己。在终止了一些交易并筹集资金后，该公司现在有望在2021年实现盈利，预计全年销售额为3.8亿美元。就上下文而言，这意味着隐含销售额增长64%。</blockquote></p><p>Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.</p><p><blockquote>目前，该公司在五个州拥有37个运营零售点，核心关注四个市场：亚利桑那州、佛罗里达州、马里兰州和宾夕法尼亚州。尽管医用大麻仅合法，但佛罗里达州仍赚了很多钱，而宾夕法尼亚州是一个有限许可州，这应该会为该公司提供一定程度的竞争保护，因为该公司的目标是吞噬份额。但随着15家商店在其家乡亚利桑那州开业，大峡谷州代表着Harvest Health最大的机会。</blockquote></p><p>Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.</p><p><blockquote>尽管Harvest Health必须向投资者证明它已经克服了早期的运营失误，但它看起来将在2021年“走向绿色”。</blockquote></p><p><img src=\"https://static.tigerbbs.com/c13ce819ae0ba9b6755b8d61f6584bbc\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>EverQuote: Implied upside of 83%</p><p><blockquote>EverQuote：隐含上涨83%</blockquote></p><p>Another small-cap stock with serious upside potential is online insurance marketplace provider<b>EverQuote</b>(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.</p><p><blockquote>另一只具有巨大上涨潜力的小盘股是在线保险市场提供商<b>EverQuote</b>（纳斯达克：永远不会）。如果分析师准确的话，根据61.58美元的一致目标价，EverQuote明年的涨幅可能高达83%。</blockquote></p><p>Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.</p><p><blockquote>谈论任何与保险有关的事情通常足以让人昏昏欲睡。EverQuote旨在通过其在线市场改变这种状况，消费者可以快速轻松地从领先的保险提供商那里获得价格政策。据该公司称，五分之一的消费者最终会在其平台上购买保单，这表明其购物者往往有积极性。换句话说，保险公司通过委托EverQuote的市场获得了更大的广告收益。</blockquote></p><p></p><p>According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.</p><p><blockquote>据该公司称，未来四年数字保险广告支出预计将每年增长16%。相比之下，保险业的广告和分销总支出（包括数字支出）预计到2024年每年仅增长4%。EverQuote正在迎合保险业增长的最佳点。</blockquote></p><p>It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.</p><p><blockquote>它也是一家一直在向新的垂直行业转型的公司。尽管汽车保险一直是其市场的支柱，但近年来它增加了房屋、租房、健康和人寿保险选项。这些新的垂直行业的增长速度比传统的汽车政策快得多。</blockquote></p><p><img src=\"https://static.tigerbbs.com/f46d76c781cc47d68033914c1c794a63\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Jushi Holdings: Implied upside of 60%</p><p><blockquote>巨石控股：隐含上涨空间60%</blockquote></p><p>Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSO<b>Jushi Holdings</b>(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.</p><p><blockquote>以防你第一次没有抓住重点，华尔街对未来12个月的大多数美国大麻股票非常乐观。小盘股MSO<b>巨石控股</b>（场外交易代码：JUSHF）也不例外。如果巨石确实达到华尔街的目标价，它将为股东带来60%的收益。</blockquote></p><p>Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.</p><p><blockquote>Harvest Health专注于四个市场，而巨石则主要专注于三个市场：宾夕法尼亚州、伊利诺伊州和弗吉尼亚州。尽管它在大约六个州都有业务，但这三个州限制了它分配零售许可证的方式。宾夕法尼亚州和伊利诺伊州限制了允许的药房数量，而弗吉尼亚州则按司法管辖区分配许可证。结论是，巨石将有一个坚实的机会在这些州建立业务，同时面临最小的竞争。</blockquote></p><p>This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.</p><p><blockquote>这也是一家不害怕将资本投入使用的公司。自今年年初以来，该公司进行了一系列收购，包括扩大其在马萨诸塞州、俄亥俄州、宾夕法尼亚州和加利福尼亚州的零售或种植足迹。</blockquote></p><p>If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.</p><p><blockquote>如果您正在寻找另一个催化剂，请考虑一下高管和内部人士在最初筹集的2.5亿美元资金中贡献了约4500万美元。当内部人士和股东的利益一致时，我们经常会看到好事发生。</blockquote></p><p><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p>Inovio Pharmaceuticals: Implied upside of 128%</p><p><blockquote>Inovio Pharmaceuticals：隐含上涨128%</blockquote></p><p>Finally, clinical-stagebiotech stock<b>Inovio Pharmaceuticals</b>(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.</p><p><blockquote>最后，临床阶段生物技术股票<b>Inovio制药公司</b>（纳斯达克：INO）被认为具有显着的上涨空间。根据15.63美元的12个月目标价计算，Inovio的股价可能会上涨一倍以上。但这是我强烈反对华尔街的一个例子。</blockquote></p><p>For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.</p><p><blockquote>在过去一年的大部分时间里，Inovio股价飙升，因为人们期望它将成为开发COVID-19疫苗的领跑者之一。但尽管通过了1期研究，Inovio在美国的2/3期试验中遇到了部分临床搁置。上周，该公司宣布INO-4800治疗新冠肺炎的3期研究将在美国境外进行，美国国防部将停止资助该公司INO-4800的后期研究。</blockquote></p><p>There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.</p><p><blockquote>这里实际上有两个问题。首先，由于美国食品和药物管理局(FDA)的部分临床搁置，Inovio已经远远落后于同行，即使INO-4800在临床研究中取得成功，它也可能无法在全球COVID-19疫苗销售中占据有意义的比例。</blockquote></p><p>Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.</p><p><blockquote>其次，四十多年后，Inovio没有什么可展示的。尽管有大量正在进行的研究，但该公司的实验性治疗方法从未获得FDA的批准。这是一个非常明显的危险信号。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/04/27/5-small-cap-stocks-60-to-140-upside-wall-street/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/27/5-small-cap-stocks-60-to-140-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112397012","content_text":"For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmarkS&P 500has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.IMAGE SOURCE: GETTY IMAGES.Vaxart: Implied upside of 140%There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stockVaxart(NASDAQ:VXRT).The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.IMAGE SOURCE: GETTY IMAGES.Harvest Health & Recreation: Implied upside of 90%With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)Harvest Health & Recreation(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.IMAGE SOURCE: GETTY IMAGES.EverQuote: Implied upside of 83%Another small-cap stock with serious upside potential is online insurance marketplace providerEverQuote(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.IMAGE SOURCE: GETTY IMAGES.Jushi Holdings: Implied upside of 60%Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSOJushi Holdings(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.IMAGE SOURCE: GETTY IMAGES.Inovio Pharmaceuticals: Implied upside of 128%Finally, clinical-stagebiotech stockInovio Pharmaceuticals(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377589110,"gmtCreate":1619535565330,"gmtModify":1634211959695,"author":{"id":"3580731839183444","authorId":"3580731839183444","name":"chantow","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3580731839183444","authorIdStr":"3580731839183444"},"themes":[],"htmlText":"TESLA FTW","listText":"TESLA FTW","text":"TESLA FTW","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/377589110","repostId":"1190086074","repostType":4,"repost":{"id":"1190086074","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1619480390,"share":"https://www.laohu8.com/m/news/1190086074?lang=zh_CN&edition=full","pubTime":"2021-04-27 07:39","market":"us","language":"en","title":"Tesla posts record net income of $438 million, revenue surges by 74%<blockquote>特斯拉净利润创纪录4.38亿美元营收暴增74%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190086074","media":"Tiger Newspress","summary":"Tesla reported record net income of $438 million during the quarter, as well as earnings of 93 cents per share on $10.39 billion in revenue.In its earnings release, the company said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.”On an earnings call, CEO Elon Musk said the delayed new version of the company’s Model S sedan will be deliv","content":"<p><b>KEY POINTS</b></p><p><blockquote><b>要点</b></blockquote></p><p><ul><li>Tesla reported record net income of $438 million during the quarter, as well as earnings of 93 cents per share on $10.39 billion in revenue.</li><li>In its earnings release, the company said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.”</li><li>On an earnings call, CEO Elon Musk said the delayed new version of the company’s Model S sedan will be delivered starting in May 2021, and Model X deliveries will begin in the third quarter of the year.</li></ul>Tesla reported first-quarter results after the bell on Monday. The company beat expectations handily, buoyed by sales of bitcoin and regulatory credits, but the stock dipped as much as 2.5% after hours as investors digested the numbers.</p><p><blockquote><ul><li>特斯拉报告本季度净利润达到创纪录的4.38亿美元，每股收益为93美分，营收为103.9亿美元。</li><li>该公司在财报中表示，通过“极快地转向新的微控制器，同时为新供应商制造的新芯片开发固件”，它已经度过了困扰汽车行业的芯片短缺问题。</li><li>在财报看涨期权上，首席执行官Elon Musk表示，该公司推迟的新版Model S轿车将于2021年5月开始交付，Model X将于今年第三季度开始交付。</li></ul>特斯拉周一盘后公布了第一季度业绩。在比特币销售和监管信贷的提振下，该公司轻松超出预期，但随着投资者消化这些数据，该股盘后下跌2.5%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/fec5c52f391c1077b749edc13b7b3417\" tg-width=\"1302\" tg-height=\"833\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Here’s how the company fared in the quarter, compared with analyst estimates compiled by Refinitiv:</p><p><blockquote>以下是该公司本季度的表现，与Refinitiv编制的分析师预期相比：</blockquote></p><p><ul><li><b>Earnings:</b>93 cents per share vs. 79 cents per share expected</li><li><b>Revenue:</b>$10.39 billion vs. $10.29 billion expected, up 74% from a year ago</li></ul>Net profit reached a quarterly record of $438 million on a GAAP basis, and the company recorded $518 million in revenue from sales of regulatory credits during the period. It also recorded a $101 million positive impact from sales of bitcoin during the quarter.</p><p><blockquote><ul><li><b>收益：</b>每股93美分，预期每股79美分</li><li><b>收入：</b>103.9亿美元，预期为102.9亿美元，同比增长74%</li></ul>按GAAP计算，净利润达到季度创纪录的4.38亿美元，该公司在此期间从监管信贷销售中获得了5.18亿美元的收入。本季度比特币销售还带来了1.01亿美元的积极影响。</blockquote></p><p><img src=\"https://static.tigerbbs.com/107ab1e725bed375ea106bdf3024ec6a\" tg-width=\"1910\" tg-height=\"1097\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>CEO Elon Musk’s electric vehicle business reported in the first quarter vehicle deliveries of 184,800 Model 3 and Model Y cars, beating expectations and setting a record for Tesla. However, the company also said it produced none of its higher-end Model S sedans or Model X SUVs for the period ending March. It delivered2,020 older Model S sedans and Model X SUVs from inventory.</p><p><blockquote>首席执行官Elon Musk的电动汽车业务报告称，第一季度Model 3和Model Y汽车交付量为18.48万辆，超出预期，创下了特斯拉的纪录。不过，该公司还表示，截至3月份，该公司没有生产任何高端Model S轿车或Model X SUV。它从库存中交付了2,020辆旧款Model S轿车和Model X SUV。</blockquote></p><p>On Monday’s earnings call, Musk said the new version of the company’s Model S sedans will finally be delivered to customers starting in May 2021, with Model X deliveries to begin in the third quarter of the year. Musk and CFO Zachary Kirkhorn both said supply chain issues are likely to remain a challenge for Tesla this year.</p><p><blockquote>在周一的财报看涨期权上，Musk表示，该公司新版Model S轿车最终将于2021年5月开始向客户交付，Model X将于今年第三季度开始交付。Musk和CFO Zachary Kirkhorn均表示，供应链问题可能仍是特斯拉今年面临的挑战。</blockquote></p><p>In January 2021 (during a fourth-quarter 2020 earnings update) Musk had said that the Model S Plaid was already in production would be delivered starting in February 2021. But he admitted on Monday, “There were more challenges than expected,” in producing the refreshed version of these vehicles. He did not elaborate.</p><p><blockquote>2021年1月（在2020年第四季度财报更新期间），马斯克曾表示，Model S Plaid已经投入生产，将于2021年2月开始交付。但他周一承认，在生产这些车辆的更新版本时，“存在比预期更多的挑战”。他没有详细说明。</blockquote></p><p>Tesla is now aiming to produce 2,000 Model S and X vehicles per week later this year.</p><p><blockquote>特斯拉目前的目标是在今年晚些时候每周生产2,000辆Model S和X汽车。</blockquote></p><p>The company said Monday it expects more than 50% vehicle delivery growth in 2021 overall, which implies minimum deliveries around 750,000 vehicles this year.</p><p><blockquote>该公司周一表示，预计2021年汽车交付量总体增长将超过50%，这意味着今年的最低交付量约为75万辆。</blockquote></p><p>The fact Tesla grew vehicle unit sales by more than 100% year over year but grew service centers by only 28% and its mobile service fleet by only 22% explains why some Tesla customers face frustratingly long wait times for repairs. Service expansion is not keeping pace with the volume of vehicles sold.</p><p><blockquote>事实上，特斯拉的汽车销量同比增长超过100%，但服务中心仅增长28%，移动服务车队仅增长22%，这解释了为什么一些特斯拉客户面临令人沮丧的漫长维修等待时间。服务扩张跟不上车辆销量的步伐。</blockquote></p><p>Tesla said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.” It did not disclose the names of its new suppliers.</p><p><blockquote>特斯拉表示，它通过“极快地转向新的微控制器，同时为新供应商制造的新芯片开发固件”，部分克服了困扰汽车行业的芯片短缺问题。它没有透露新供应商的名称。</blockquote></p><p>It also reiterated Musk’s frequent claim that cameras, not radar, are a better path toward autonomous vehicles. “Our AI-based software architecture has been increasingly reliant on cameras, to the point where radar is becoming unnecessary earlier than expected. As a result, our FSD [Full Self-Driving] team is fully focused on evolving to a vision-based autonomous system and we are nearly ready to switch the US market to Tesla Vision,” the company said in its earnings release.</p><p><blockquote>它还重申了马斯克经常声称的摄像头而不是雷达是自动驾驶汽车的更好途径。“我们基于人工智能的软件架构越来越依赖摄像头，以至于雷达比预期更早变得不必要。因此，我们的FSD（全自动驾驶）团队完全专注于向基于视觉的自动驾驶系统发展，我们几乎准备好将美国市场转向特斯拉视觉，”该公司在财报中表示。</blockquote></p><p>Revenue for its energy generation and storage business nearly doubled for Tesla versus the same period in 2020, when Musk said Covid, then an emerging pandemic, had slowed its energy business to a crawl. But energy revenue declined from $787 million in the fourth quarter to $595 million in the first quarter of 2021.</p><p><blockquote>与2020年同期相比，特斯拉能源发电和存储业务的收入几乎翻了一番，当时马斯克表示，当时新冠疫情是一种新兴流行病，导致其能源业务放缓。但能源收入从第四季度的7.87亿美元下降至2021年第一季度的5.95亿美元。</blockquote></p><p>Recently, Tesla increased prices for its solar rooftops by 50%, and now requires anyone ordering solar photovoltaics (including Tesla solar roof tiles) to also order the Powerwall, Tesla’s home energy storage system. The sudden price change applied retroactively to some vexed customers.</p><p><blockquote>最近，特斯拉将其太阳能屋顶的价格提高了50%，现在要求任何订购太阳能光伏（包括特斯拉太阳能屋顶瓦片）的人也必须订购特斯拉的家庭储能系统Powerwall。突然的价格变化追溯适用于一些恼怒的顾客。</blockquote></p><p>Musk said on the Q1 2021 call that he is aiming for homes with solar rooftops and batteries from Tesla to function as a “giant distributed utility” that can help incumbent electrical utilities supply customers with all the electricity they need as demand and extreme weather events increase.</p><p><blockquote>马斯克在2021年第一季度看涨期权上表示，他的目标是让拥有太阳能屋顶和特斯拉电池的家庭成为“巨型分布式公用事业公司”，可以帮助现有电力公司在需求和极端天气事件增加时为客户提供所需的所有电力。</blockquote></p><p></p><p>Executives did not say how they would change their production or mix of battery cells from suppliers in order to make a higher volume of vehicles and energy storage products in 2021.</p><p><blockquote>高管们没有透露他们将如何改变供应商的电池生产或组合，以便在2021年生产更多的汽车和储能产品。</blockquote></p><p>Musk said the company’s 4680 cells, which it developed independently and makes at a pilot plant in Fremont, California, are not yet reliable enough to be shipped in Tesla vehicles. He said Tesla would probably “achieve volume production” of these cells in 12 to 18 months.</p><p><blockquote>Musk表示，该公司自主开发并在加州Fremont的一家试点工厂生产的4680电池还不够可靠，无法用特斯拉汽车运输。他表示，特斯拉可能会在12至18个月内“实现批量生产”这些电池。</blockquote></p><p>The company revealed in February it purchased $1.5 billion in bitcoin and would potentially invest in other cryptocurrencies in the future. By April, bitcoin rose to record levels before pulling back. In its statement of cash flows, Tesla revealed that it had sold $272 million worth of “digital assets,” presumably bitcoin, during the quarter.</p><p><blockquote>该公司在2月份透露，它购买了15亿美元的比特币，并可能在未来投资其他加密货币。到4月份，比特币升至创纪录水平，然后回落。特斯拉在其现金流量表中透露，该公司在本季度出售了价值2.72亿美元的“数字资产”，可能是比特币。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla posts record net income of $438 million, revenue surges by 74%<blockquote>特斯拉净利润创纪录4.38亿美元营收暴增74%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla posts record net income of $438 million, revenue surges by 74%<blockquote>特斯拉净利润创纪录4.38亿美元营收暴增74%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-04-27 07:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>KEY POINTS</b></p><p><blockquote><b>要点</b></blockquote></p><p><ul><li>Tesla reported record net income of $438 million during the quarter, as well as earnings of 93 cents per share on $10.39 billion in revenue.</li><li>In its earnings release, the company said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.”</li><li>On an earnings call, CEO Elon Musk said the delayed new version of the company’s Model S sedan will be delivered starting in May 2021, and Model X deliveries will begin in the third quarter of the year.</li></ul>Tesla reported first-quarter results after the bell on Monday. The company beat expectations handily, buoyed by sales of bitcoin and regulatory credits, but the stock dipped as much as 2.5% after hours as investors digested the numbers.</p><p><blockquote><ul><li>特斯拉报告本季度净利润达到创纪录的4.38亿美元，每股收益为93美分，营收为103.9亿美元。</li><li>该公司在财报中表示，通过“极快地转向新的微控制器，同时为新供应商制造的新芯片开发固件”，它已经度过了困扰汽车行业的芯片短缺问题。</li><li>在财报看涨期权上，首席执行官Elon Musk表示，该公司推迟的新版Model S轿车将于2021年5月开始交付，Model X将于今年第三季度开始交付。</li></ul>特斯拉周一盘后公布了第一季度业绩。在比特币销售和监管信贷的提振下，该公司轻松超出预期，但随着投资者消化这些数据，该股盘后下跌2.5%。</blockquote></p><p><img src=\"https://static.tigerbbs.com/fec5c52f391c1077b749edc13b7b3417\" tg-width=\"1302\" tg-height=\"833\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Here’s how the company fared in the quarter, compared with analyst estimates compiled by Refinitiv:</p><p><blockquote>以下是该公司本季度的表现，与Refinitiv编制的分析师预期相比：</blockquote></p><p><ul><li><b>Earnings:</b>93 cents per share vs. 79 cents per share expected</li><li><b>Revenue:</b>$10.39 billion vs. $10.29 billion expected, up 74% from a year ago</li></ul>Net profit reached a quarterly record of $438 million on a GAAP basis, and the company recorded $518 million in revenue from sales of regulatory credits during the period. It also recorded a $101 million positive impact from sales of bitcoin during the quarter.</p><p><blockquote><ul><li><b>收益：</b>每股93美分，预期每股79美分</li><li><b>收入：</b>103.9亿美元，预期为102.9亿美元，同比增长74%</li></ul>按GAAP计算，净利润达到季度创纪录的4.38亿美元，该公司在此期间从监管信贷销售中获得了5.18亿美元的收入。本季度比特币销售还带来了1.01亿美元的积极影响。</blockquote></p><p><img src=\"https://static.tigerbbs.com/107ab1e725bed375ea106bdf3024ec6a\" tg-width=\"1910\" tg-height=\"1097\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>CEO Elon Musk’s electric vehicle business reported in the first quarter vehicle deliveries of 184,800 Model 3 and Model Y cars, beating expectations and setting a record for Tesla. However, the company also said it produced none of its higher-end Model S sedans or Model X SUVs for the period ending March. It delivered2,020 older Model S sedans and Model X SUVs from inventory.</p><p><blockquote>首席执行官Elon Musk的电动汽车业务报告称，第一季度Model 3和Model Y汽车交付量为18.48万辆，超出预期，创下了特斯拉的纪录。不过，该公司还表示，截至3月份，该公司没有生产任何高端Model S轿车或Model X SUV。它从库存中交付了2,020辆旧款Model S轿车和Model X SUV。</blockquote></p><p>On Monday’s earnings call, Musk said the new version of the company’s Model S sedans will finally be delivered to customers starting in May 2021, with Model X deliveries to begin in the third quarter of the year. Musk and CFO Zachary Kirkhorn both said supply chain issues are likely to remain a challenge for Tesla this year.</p><p><blockquote>在周一的财报看涨期权上，Musk表示，该公司新版Model S轿车最终将于2021年5月开始向客户交付，Model X将于今年第三季度开始交付。Musk和CFO Zachary Kirkhorn均表示，供应链问题可能仍是特斯拉今年面临的挑战。</blockquote></p><p>In January 2021 (during a fourth-quarter 2020 earnings update) Musk had said that the Model S Plaid was already in production would be delivered starting in February 2021. But he admitted on Monday, “There were more challenges than expected,” in producing the refreshed version of these vehicles. He did not elaborate.</p><p><blockquote>2021年1月（在2020年第四季度财报更新期间），马斯克曾表示，Model S Plaid已经投入生产，将于2021年2月开始交付。但他周一承认，在生产这些车辆的更新版本时，“存在比预期更多的挑战”。他没有详细说明。</blockquote></p><p>Tesla is now aiming to produce 2,000 Model S and X vehicles per week later this year.</p><p><blockquote>特斯拉目前的目标是在今年晚些时候每周生产2,000辆Model S和X汽车。</blockquote></p><p>The company said Monday it expects more than 50% vehicle delivery growth in 2021 overall, which implies minimum deliveries around 750,000 vehicles this year.</p><p><blockquote>该公司周一表示，预计2021年汽车交付量总体增长将超过50%，这意味着今年的最低交付量约为75万辆。</blockquote></p><p>The fact Tesla grew vehicle unit sales by more than 100% year over year but grew service centers by only 28% and its mobile service fleet by only 22% explains why some Tesla customers face frustratingly long wait times for repairs. Service expansion is not keeping pace with the volume of vehicles sold.</p><p><blockquote>事实上，特斯拉的汽车销量同比增长超过100%，但服务中心仅增长28%，移动服务车队仅增长22%，这解释了为什么一些特斯拉客户面临令人沮丧的漫长维修等待时间。服务扩张跟不上车辆销量的步伐。</blockquote></p><p>Tesla said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.” It did not disclose the names of its new suppliers.</p><p><blockquote>特斯拉表示，它通过“极快地转向新的微控制器，同时为新供应商制造的新芯片开发固件”，部分克服了困扰汽车行业的芯片短缺问题。它没有透露新供应商的名称。</blockquote></p><p>It also reiterated Musk’s frequent claim that cameras, not radar, are a better path toward autonomous vehicles. “Our AI-based software architecture has been increasingly reliant on cameras, to the point where radar is becoming unnecessary earlier than expected. As a result, our FSD [Full Self-Driving] team is fully focused on evolving to a vision-based autonomous system and we are nearly ready to switch the US market to Tesla Vision,” the company said in its earnings release.</p><p><blockquote>它还重申了马斯克经常声称的摄像头而不是雷达是自动驾驶汽车的更好途径。“我们基于人工智能的软件架构越来越依赖摄像头，以至于雷达比预期更早变得不必要。因此，我们的FSD（全自动驾驶）团队完全专注于向基于视觉的自动驾驶系统发展，我们几乎准备好将美国市场转向特斯拉视觉，”该公司在财报中表示。</blockquote></p><p>Revenue for its energy generation and storage business nearly doubled for Tesla versus the same period in 2020, when Musk said Covid, then an emerging pandemic, had slowed its energy business to a crawl. But energy revenue declined from $787 million in the fourth quarter to $595 million in the first quarter of 2021.</p><p><blockquote>与2020年同期相比，特斯拉能源发电和存储业务的收入几乎翻了一番，当时马斯克表示，当时新冠疫情是一种新兴流行病，导致其能源业务放缓。但能源收入从第四季度的7.87亿美元下降至2021年第一季度的5.95亿美元。</blockquote></p><p>Recently, Tesla increased prices for its solar rooftops by 50%, and now requires anyone ordering solar photovoltaics (including Tesla solar roof tiles) to also order the Powerwall, Tesla’s home energy storage system. The sudden price change applied retroactively to some vexed customers.</p><p><blockquote>最近，特斯拉将其太阳能屋顶的价格提高了50%，现在要求任何订购太阳能光伏（包括特斯拉太阳能屋顶瓦片）的人也必须订购特斯拉的家庭储能系统Powerwall。突然的价格变化追溯适用于一些恼怒的顾客。</blockquote></p><p>Musk said on the Q1 2021 call that he is aiming for homes with solar rooftops and batteries from Tesla to function as a “giant distributed utility” that can help incumbent electrical utilities supply customers with all the electricity they need as demand and extreme weather events increase.</p><p><blockquote>马斯克在2021年第一季度看涨期权上表示，他的目标是让拥有太阳能屋顶和特斯拉电池的家庭成为“巨型分布式公用事业公司”，可以帮助现有电力公司在需求和极端天气事件增加时为客户提供所需的所有电力。</blockquote></p><p></p><p>Executives did not say how they would change their production or mix of battery cells from suppliers in order to make a higher volume of vehicles and energy storage products in 2021.</p><p><blockquote>高管们没有透露他们将如何改变供应商的电池生产或组合，以便在2021年生产更多的汽车和储能产品。</blockquote></p><p>Musk said the company’s 4680 cells, which it developed independently and makes at a pilot plant in Fremont, California, are not yet reliable enough to be shipped in Tesla vehicles. He said Tesla would probably “achieve volume production” of these cells in 12 to 18 months.</p><p><blockquote>Musk表示，该公司自主开发并在加州Fremont的一家试点工厂生产的4680电池还不够可靠，无法用特斯拉汽车运输。他表示，特斯拉可能会在12至18个月内“实现批量生产”这些电池。</blockquote></p><p>The company revealed in February it purchased $1.5 billion in bitcoin and would potentially invest in other cryptocurrencies in the future. By April, bitcoin rose to record levels before pulling back. In its statement of cash flows, Tesla revealed that it had sold $272 million worth of “digital assets,” presumably bitcoin, during the quarter.</p><p><blockquote>该公司在2月份透露，它购买了15亿美元的比特币，并可能在未来投资其他加密货币。到4月份，比特币升至创纪录水平，然后回落。特斯拉在其现金流量表中透露，该公司在本季度出售了价值2.72亿美元的“数字资产”，可能是比特币。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190086074","content_text":"KEY POINTSTesla reported record net income of $438 million during the quarter, as well as earnings of 93 cents per share on $10.39 billion in revenue.In its earnings release, the company said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.”On an earnings call, CEO Elon Musk said the delayed new version of the company’s Model S sedan will be delivered starting in May 2021, and Model X deliveries will begin in the third quarter of the year.Tesla reported first-quarter results after the bell on Monday. The company beat expectations handily, buoyed by sales of bitcoin and regulatory credits, but the stock dipped as much as 2.5% after hours as investors digested the numbers.Here’s how the company fared in the quarter, compared with analyst estimates compiled by Refinitiv:Earnings:93 cents per share vs. 79 cents per share expectedRevenue:$10.39 billion vs. $10.29 billion expected, up 74% from a year agoNet profit reached a quarterly record of $438 million on a GAAP basis, and the company recorded $518 million in revenue from sales of regulatory credits during the period. It also recorded a $101 million positive impact from sales of bitcoin during the quarter.CEO Elon Musk’s electric vehicle business reported in the first quarter vehicle deliveries of 184,800 Model 3 and Model Y cars, beating expectations and setting a record for Tesla. However, the company also said it produced none of its higher-end Model S sedans or Model X SUVs for the period ending March. It delivered2,020 older Model S sedans and Model X SUVs from inventory.On Monday’s earnings call, Musk said the new version of the company’s Model S sedans will finally be delivered to customers starting in May 2021, with Model X deliveries to begin in the third quarter of the year. Musk and CFO Zachary Kirkhorn both said supply chain issues are likely to remain a challenge for Tesla this year.In January 2021 (during a fourth-quarter 2020 earnings update) Musk had said that the Model S Plaid was already in production would be delivered starting in February 2021. But he admitted on Monday, “There were more challenges than expected,” in producing the refreshed version of these vehicles. He did not elaborate.Tesla is now aiming to produce 2,000 Model S and X vehicles per week later this year.The company said Monday it expects more than 50% vehicle delivery growth in 2021 overall, which implies minimum deliveries around 750,000 vehicles this year.The fact Tesla grew vehicle unit sales by more than 100% year over year but grew service centers by only 28% and its mobile service fleet by only 22% explains why some Tesla customers face frustratingly long wait times for repairs. Service expansion is not keeping pace with the volume of vehicles sold.Tesla said it has weathered chip shortages that have plagued the auto industry in part by “pivoting extremely quickly to new microcontrollers, while simultaneously developing firmware for new chips made by new suppliers.” It did not disclose the names of its new suppliers.It also reiterated Musk’s frequent claim that cameras, not radar, are a better path toward autonomous vehicles. “Our AI-based software architecture has been increasingly reliant on cameras, to the point where radar is becoming unnecessary earlier than expected. As a result, our FSD [Full Self-Driving] team is fully focused on evolving to a vision-based autonomous system and we are nearly ready to switch the US market to Tesla Vision,” the company said in its earnings release.Revenue for its energy generation and storage business nearly doubled for Tesla versus the same period in 2020, when Musk said Covid, then an emerging pandemic, had slowed its energy business to a crawl. But energy revenue declined from $787 million in the fourth quarter to $595 million in the first quarter of 2021.Recently, Tesla increased prices for its solar rooftops by 50%, and now requires anyone ordering solar photovoltaics (including Tesla solar roof tiles) to also order the Powerwall, Tesla’s home energy storage system. The sudden price change applied retroactively to some vexed customers.Musk said on the Q1 2021 call that he is aiming for homes with solar rooftops and batteries from Tesla to function as a “giant distributed utility” that can help incumbent electrical utilities supply customers with all the electricity they need as demand and extreme weather events increase.Executives did not say how they would change their production or mix of battery cells from suppliers in order to make a higher volume of vehicles and energy storage products in 2021.Musk said the company’s 4680 cells, which it developed independently and makes at a pilot plant in Fremont, California, are not yet reliable enough to be shipped in Tesla vehicles. He said Tesla would probably “achieve volume production” of these cells in 12 to 18 months.The company revealed in February it purchased $1.5 billion in bitcoin and would potentially invest in other cryptocurrencies in the future. By April, bitcoin rose to record levels before pulling back. In its statement of cash flows, Tesla revealed that it had sold $272 million worth of “digital assets,” presumably bitcoin, during the quarter.","news_type":1,"symbols_score_info":{"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":3264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
